Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 30, 2023
OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 6, 2023
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 12, 2023
A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 13, 2023
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 13, 2023
Phase II Multicenter Trial of Iberdomide as Maintenance Therapy for Multiple Myeloma Patients with Sub Optimal Response After Autologous Hematopoietic Stem Cell Transplant (AHCT)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 14, 2023
C-800-25: A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) for the Treatment of Advanced, Refractory Microsatellite Stable Colorectal Cancer Without Liver Metastases
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 14, 2023
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-Expressing Metastatic Castrate Resistant Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 12, 2023
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 14, 2023
A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination with Enzalutamide (Xtandi) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 14, 2023